

# CONTENTS

---

Summary of International Consultation on Urologic Disease Modified Oxford Center for Evidence-based Medicine Grading System for Guideline Recommendations	10
<b>Committee 1 Bladder Cancer: Epidemiology, Staging and Grading, and Diagnosis</b>	<b>13</b>
<i>Z. KIRKALI (TURKEY), T. CHAN (USA), M. MANOHARAN (USA), F. ALGABA (SPAIN), C. BUSCH (SWEDEN), L. CHENG (USA), L. KIEMENEY (NETHERLANDS), M. KRIEGMAIR (GERMANY), R. MONTIRONI (ITALY), W. MURPHY (USA), I. SESTERHENN (USA), M. TACHIBANA (JAPAN), J. WEIDER (USA)</i>	
<b>Committee 2 Cytology And Tumor Markers:Tumor Markers Beyond Cytology</b>	<b>65</b>
<i>V. B. LOKESHWAR (USA), T. HABUCHI (JAPAN), H. B. GROSSMAN (USA), W. M. MURPHY (USA), G. P. HEMSTREET, III (USA), S. H. HAUTMANN (GERMANY), A. V. BONO (ITALY), R. H. GETZENBERG (USA), P. GOEBELL (GERMANY), B. J. SCHMITZ-DRÄGER (GERMANY), M. MARBERGER (AUSTRIA), J. A. SCHALKEN (NETHERLANDS), E. MESSING (USA), Y. FRADET (CANADA), M. J. DROLLER (USA)</i>	
<b>Committee 3 Low Grade, Ta (Noninvasive) Urothelial Carcinoma of the Bladder</b>	<b>139</b>
<i>W. OOSTERLINCK (BELGIUM), E. SOLSONA (SPAIN), H. AKAZA (JAPAN), C. BUSCH (SWEDEN), P. J. GOEBELL (GERMANY), P.-U. MALMSTRÖM (SWEDEN), H. ÖZEN (TURKEY), P. SVED (USA)</i>	
<b>Committee 4 High Grade Ta Urothelial Carcinoma and Carcinoma in Situ of the Bladder</b>	<b>165</b>
<i>R. SYLVESTER (BELGIUM), A. V.D. MEIJDEN (NETHERLANDS), J.A. WITJES (NETHERLANDS), G. JAKSE (GERMANY), N. NONOMURA (JAPAN), C. CHENG (SINGAPORE), A. TORRES (MEXICO), R. WATSON (AUSTRALIA), K.H. KURTH (NETHERLANDS)</i>	
<b>Committee 5 T1 Urothelial Carcinoma of the Bladder</b>	<b>189</b>
<i>M.A.S. JEWETT (CANADA), A.M. NIEDER (USA), M. BRAUSI (ITALY), D. LAMM (USA), M. O'DONNELL (USA), K. TOMITA (JAPAN), H. WOO (AUSTRALIA)</i>	
<b>Committee 6 Muscle-Invasive Urothelial Carcinoma of the Bladder</b>	<b>219</b>
<i>S. B. MALKOWICZ (USA), H. VAN POPPEL (BELGIUM), G. MICKISCH (GERMANY), V. PANSADORO (ITALY), J. THÜROFF (GERMANY), M. SOLOWAY (USA), S. CHANG (USA), M. BENSON (USA), I. FUKUI (JAPAN)</i>	

- Committee 7 Urinary Diversion** **239**  
*R. E. HAUTMANN (GERMANY), H. ABOL-ENEIN (EGYPT), K. HAFEZ (USA),  
I. HARA (JAPAN), W. MANSSON (SWEDEN), R. D. MILLS (UK), J. D. MONTIE (USA),  
A. I. SAGALOWSKY (USA), J. P. STEIN (USA), A. STENZL (GERMANY),  
U. E. STUDER (SWITZERLAND), B. G. VOLKMER (GERMANY)*
- Committee 8 Urothelial Carcinoma of the Prostate** **309**  
*J. PALOU (SPAIN), J. BANIEL (ISRAEL), L. KLOTZ (CANADA), D. WOOD (USA),  
M. COOKSON (USA), S. LERNER (USA), S. HORIE (JAPAN), M. SCHOENBERG (USA),  
J. ANGULO (SPAIN), P. BASSI (ITALY)*
- Committee 9 Chemotherapy for Bladder Cancer: Treatment Guidelines  
for Neoadjuvant Chemotherapy, Bladder Preservation,  
Adjuvant Chemotherapy, and Metastatic Cancer** **335**  
*C. STERNBERG (ITALY), S. M. DONAT (USA), J. BELLMUNT (SPAIN),  
R. E. MILLIKAN (USA), W. STADLER (USA), P. DE MULDER (NETHERLANDS),  
A. SHERIF (SWEDEN), H. VON DER MAASE (DENMARK), T. TSUKAMOTO (JAPAN),  
M. SOLOWAY (USA)*
- Committee 10 Radiotherapy for Bladder Cancer** **359**  
*M. MILOSEVIC (CANADA), M. GOSPODAROWICZ (CANADA), A. ZIETMAN (USA),  
F. ABBAS (PAKISTAN), K. HAUSTERMANS (BELGIUM), L. MOONEN (NETHERLANDS),  
C. RÖDEL (GERMANY), M. SCHOENBERG (USA), W. SHIPLEY (USA)*
- Committee 11 Non-urothelial Cancer of the Bladder** **383**  
*H. ABOL-ENEIN (EGYPT), B.R. KAVA (USA), A.J.K. CARMACK (USA)*